Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy

Expert Opinion on Biological Therapy

Volumn 5, Issue 9, 2005, Pages 1183-1192

  Bendle, Gavin M ^b   Holler, Angelika ^b   Downs, Anne Marie ^b   Xue, Shao An ^b   Stauss, Hans J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

Adoptive transfer; Allo restricted CTL; Immunotherapy; MDM2; T cell tolerance; TCR gene transfer; Tumour associated antigen

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYCLIN D1; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA ANTIGEN 1; PROTEIN MDM2; PROTEIN P53; RECOMBINANT ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENE TRANSFER; HUMAN; IMMUNOLOGICAL TOLERANCE; MELANOMA; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; GENE THERAPY; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MODELS, ANIMAL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 24144471801     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.9.1183     Document Type: Review

References (89)

1. KOLB HJ, MITTERMULLER J, CLEMM C et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 76(12):2462-2465.
2. VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643-1647. First report of a human CTL-recognised TAA.
3. RENKVIST N, CASTELLI C, ROBBINS PE PARMIANI G: A listing of human tumor antigens recognised by T cells. Cancer Immunol. Immunother. (2001) 50:3-15.
4. SKIPPER J, STAUSS HJ: Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J. Exp. Med. (1993) 177(5):1493-1498.
5. CLARK RE, DODI IA, HILL SC et al.: Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood (2001) 98(10):2887-2893.
6. JANETZKI S, PALLA D, ROSENHAUER V et al.: Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int. J. Cancer (2000) 88(2):232-238.
7. CASTELLI C, RIVOLTINI L, RINI F et al.: Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol. Immunother. (2004) 53:227-233.
8. JAGER E, CHEN YT, DRIJFHOUT JW et al.: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. (1998) 187(2):265-270.
9. ROSENBERG SA: Progress in human tumour immunology and immunotherapy. Nature (2001) 411(6835):380-384.
10. KAWAKAMI Y, ELIYAHU S, DELGADO CH et al.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA (1994) 91(9):3515-3519.
11. VIERBOOM MP, NIJMAN HW, OFFRINGA R et al.: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. (1997) 186(5):695-704. Demonstration that high-avidity p53-specific CTLs can provide tumour protection without causing damage to normal tissues in mice.
12. SADOVNIKOVA E, STAUSS HJ: Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA (1996) 93(23):13114-13118. The allo-restricted approach was used to circumvent T cell tolerance in mice and generate high-avidity tumour-reactive CTLs specific for a peptide epitope of MDM2.
13. SADOVNIKOVA E, JOPLING LA, SOO KS, STAUSS HJ: Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol. (1998) 28(1):193-200. A study describing the use of the allo-restricted approach to generate human high-avidity CTLs specific for the broadly expressed TAA cyclin-D1.
14. FREEDMAN DA, LEVINE AJ: Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. (1999) 59(1):1-7.
15. MOMAND J, WU HH, DASGUPTA G: MDM2-master regulator of the p53 tumor suppressor protein. Gene (2000) 242(1-2):15-29.
16. VOGELSTEIN B, LANE D, LEVINE AJ: Surfing the p53 network. Nature (2000) 408(6810):307-310.
17. JONES SN, ROE AE, DONEHOWER LA, BRADLEY A: Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (1995) 378(6553):206-208.
18. FAKHARZADEH SS, TRUSKO SP, GEORGE DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. (1991) 10(6):1565-1569.
19. MOMAND J, ZAMBETTI GP, OLSON DC, GEORGE D, LEVINE AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 69(7):1237-1245.
20. TROTTA R, VIGNUDELLI T, CANDINI O et al.: BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell (2003) 3(2):145-160.
21. OLINER JD, KINZLER KW, MELTZER PS, GEORGE DL, VOGELSTEIN B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 358(6381):80-83.
22. BUESO-RAMOS CE, YANG Y, DELEON E et al.: The human MDM-2 oncogene is overexpressed in leukemias. Blood (1993) 82(9):26l7-2623.
23. REIFENBERGER G, LIU L, ICHIMURA K, SCHMIDT EE, COLLINS VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. (1993) 53(12):2736-2739.
24. MOMAND J, ZAMBETTI GP: Mdm-2: 'big brother' of p53. J. Cell. Biochem. (1997) 64(3):343-352.
25. CORDARO TA, DE VISSER KE, TIRION FH, SCHUMACHER TN, KRUISBEEK AM: Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J. Immunol. (2002) 168(2):651-660.
26. MORGAN DJ, KREUWEL HT, FLECK S et al.: Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. (1998) 160(2):643-651.
27. ZEH HJ 3RD, PERRY-LALLEY D, DUDLEY ME, ROSENBERG SA, YANG JC: High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. (1999) 162(2):989-994.
28. YANG S, LINETTE GP, LONGERICH S, HALUSKA FG: Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J. Immunol. (2002) 169(1):531-539.
29. ALEXANDER-MILLER MA, LEGGATT GR, BERZOFSKY JA: Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA (1996) 93:4102-4107.
30. HOLLER PD, HOLMAN PO, SHUSTA EV et al.: In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA (2000) 97(10):5387-5392.
31. RUBINSTEIN MP, KADIMA AN, SALEM ML et al.: Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J. Immunol. (2003) 170:1209-1217.
32. LABRECQUE N, WHITFIELD LS, OBST R et al.: How much TCR does a T cell need? Immunity (2001) 15(1):71-82.
33. CAWTHON AG, LU H, ALEXANDER-MILLER MA: Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8alphabeta versus CD8alphaalpha expression. J. Immunol. (2001) 167(5):2577-2584.
34. BACHMANN MF, BARNER M, KOPF M: CD2 sets quantitative thresholds in T cell activation. J. Exp. Med. (1999) 190(10):1383-1391.
35. LUDEWIG B, OCHSENBEIN AF, ODERMATT B et al.: Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. (2000) 191(5):795-804.
36. GILBOA E: The risk of autoimmunity associated with tumor immunotherapy. Nat. Immunol. (2001) 2(9):789-792.
37. VAN ELSAS A, SUTMULLER RP, HURWITZ AA et al.: Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. (2001) 194(4):481-489.
38. ROMIEU R, BARATIN M, KAYIBANDA M et al.: Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J. Immunol. (1998) 161(10):5133-5137. Demonstration that vaccine-induced low-avidity CTLs are less effective than adoptively transferred high-avidity CTLs at controlling tumour growth in vivo.
39. SCHELL TD, MYLIN LM, GEORGOFF I et al.: Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J. Virol. (1999) 73(7):5981-5993.
40. GRANZIERO L, KRAJEWSKI S, FARNESS P et al.: Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur. J. Immunol. (1999) 29(4):1127-1138.
41. MANDELBOIM O, VADAI E, FRIDKIN M et al.: Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. (1995) 1(11):1179-1183.
42. MERAD M, SUGIE T, ENGLEMAN EG, FONG L: In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood (2002) 99(5):1676-1682.
43. OCHSENBEIN AF, KLENERMAN P, KARRER U et al.: Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA (1999) 96(5):2233-2238.
44. THEOBALD M, BIGGS J, HERNANDEZ J et al.: Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. (1997) 185(5):833-841. A study illustrating the effects of immunological tolerance on the CTL repertoire specific for p53 in HLA-A2 transgenic mice.
45. DAHL AM, BEVERLEY PC, STAUSS HJ: A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol. (1996) 157(1):239-246. A report investigating whether tumour-reactive self-MHC-restricted murine CTLs specific for peptide epitopes of MDM2 can be generated in vitro.
46. RAMIREZ F, GHANI Y, STAUSS H: Incomplete tolerance to the tumour-associated antigen MDM2. Int. Immunol. (2004) 16(2):327-334. A study demonstrating that MDM2 peptide vaccination does not prevent the growth of MDM2-expressing tumours in mice.
47. STANISLAWSKI T, VOSS RH, LOTZ C et al.: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. (2001) 2(10):962-970. HLA-A2 transgenic mice were used to circumvent T cell tolerance and generate high-avidity HLA-A2-restricted MDM2-specific CTLs. Retroviral transfer of the TCR genes isolated from the CTLs generated human tumour-reactive MDM2-specific CTLs.
48. BENDLE GM, HOLLER A, PANG LK et al.: Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res. (2004) 64(21):8052-8056. Demonstration that adoptive immunotherapy with high-avidity MDM2-specific CTLs can be safe, but the induction of tolerance in transferred CTLs may limit their therapeutic efficacy.
49. ROSENBERG SA, YANG JC, RESTIFO NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10(9):909-915.
50. OKA Y, TSUBOI A, TAGUCHI T et al.: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA (2004) 101(38):13885-13890.
51. FONG L, HOU Y, RIVAS A et al.: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA (2001) 98(15):8809-8814.
52. BANCHEREAU J, PALUCKA AK, DHODAPKAR M et al.: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. (2001) 61(17):6451-6458.
53. GERMEAU C, MA W, SCHIAVETTI F et al.: High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. (2005) 201(2):241-248.
54. LURQUIN C, LETHE B, DE PLAEN E et al.: Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. (2005) 201(2):249-257.
55. RIBAS A, TIMMERMAN JM, BUTTERFIELD LH, ECONOMOU JS: Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. (2003) 24(2):58-61.
56. HOROWITZ MM, GALE RP, SONDEL PM et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 75(3):555-562.
57. DEN HAAN JM, SHERMAN NE, BLOKLAND E et al.: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science (1995) 268(5216):1476-1480.
58. SHLOMCHIK WD, COUZENS MS, TANG CB et al.: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 285(5426):412-415.
59. YEE C, THOMPSON JA, BYRD D et al.: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA (2002) 99(25):16168-16173.
60. ROSENBERG SA, DUDLEY ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA (2004) 101(Suppl. 2):14639-14645.
61. DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-854.
62. OVERWIJK WW, THEORET MR, FINKELSTEIN SE et al.: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. (2003) 198(4):569-580.
63. KESSELS HW, VAN DEN BOOM MD, SPITS H, HOOIJBERG E, SCHUMACHER TN: Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA (2000) 97(26):14578-14583. A study demonstrating that in vitro mutagenesis of TCRs can be used to change their affinity and/or specificity, thereby circumventing T cell tolerance.
64. STAUSS HJ: Immunotherapy with CTLs restricted by nonself MHC. Immunol. Today (1999) 20(4):180-183.
65. GAO L, BELLANTUONO I, ELSASSER A et al.: Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood(2000) 95(7):2198-2203.
66. KLEBANOFF CA, KHONG HT, ANTONY PA, PALMER DC, RESTIFO NP: Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. (2005) 26(2):111-117.
67. + helper T cells.
68. CLAY TM, CUSTER MC, SACHS J et al.: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. (1999) 163(1):507-513.
69. KESSELS HW, WOLKERS MC, VAN DEN BOOM MD, VAN DER VALK MA, SCHUMACHER TN: Immunotherapy through TCR gene transfer. Nat. Immunol. (2001) 2(10):957-961. The first study showing that TCR-transduced T cells can persist and function in vivo in mice.
70. MORGAN RA, DUDLEY ME, YU YY et al.: High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. (2003) 171(6):3287-3295.
71. MORAHAN G, ALLISON J, MILLER JF: Tolerance of class I histocompatibility antigens expressed extrathymically. Nature (1989) 339(6226):622-624.
72. ROCHA B, TANCHOT C, VON BOEHMER H: Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J. Exp. Med. (1993) 177(5):1517-1521.
73. TOES RE, OSSENDORP F, OFFRINGA R, MELIEF CJ: CD4 T cells and their role in antitumor immune responses. J. Exp. Med. (1999) 189(5):753-756.
74. WANG RF: The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. (2001) 22(5):269-276.
75. OSSENDORP F, MENGEDE E, CAMPS M, FILIUS R, MELIEF CJ: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. (1998) 187(5):693-702.
76. SHRIKANT P, MESCHER MF: Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J. Immunol. (2002) 169(4):1753-1759.
77. MARZO AL, KINNEAR BF, LAKE RA et al.: Tumor-specific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J. Immunol. (2000) 165(11):6047-6055.
78. BOURGEOIS C, ROCHA B, TANCHOT C: A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science (2002) 297(5589):2060-2063.
79. JANSSEN EM, LEMMENS EE, WOLFE T et al.: CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 421(6925):852-856.
80. SUN JC, WILLIAMS MA, BEVAN MJ: CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. (2004) 5(9):927-933.
81. QIN Z, BLANKENSTEIN T: CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity (2000) 12(6):677-686.
82. TOPALIAN SL, RIVOLTINI L, MANCINI M et al.: Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA (1994) 91(20):9461-9465.
83. DENGJEL J, DECKER P, SCHOOR O et al.: Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur.J. Immunol. (2004) 34(12):3644-3651.
84. + helper T cells can persist in vivo, and provide help for CTL-mediated tumour rejection and the development of T cell memory in mice.
85. WILLEMSEN R, RONTELTAP C, HEUVELING M, DEBETS R, BOLHUIS R: Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCRαβ gene transfer requires CD8α. Gene Ther. (2005) 12:140-146.
86. ROSZKOWSKI JJ, LYONS GE, KAST WM et al.: Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. (2005) 65(4):1570-1576.
87. CHENG LE, OHLEN C, NELSON BH, GREENBERG PD: Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. USA (2002) 99(5):3001-3006.
88. LOU Y, WANG G, LIZEE G et al.: Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. (2004) 64(18):6783-6790. A study showing that DC vaccination can improve the tumour-protective efficacy of adoptively transferred CTLs in mice.
89. VONDERHEIDE RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene (2002) 21(4):674-679.